-
Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
-
In this downloadable slideset, Margaret Callahan, MD, PhD; Shirish Gadgeel, MD; Ryan T. Merrell, MD; Bradley J. Monk, MD, FACS, FACOG; and Joyce O’Shaughnessy, MD, review important clinical presentations across multiple cancers from the 2016 oncology meeting in Copenhagen.
-
Ravi Salgia, MD, provides expert perspective on results of studies of MET-targeted agents being evaluated in a variety of tumor types.
-
Ahmad Tarhini, MD, PhD, reviews the role of the VEGF pathway in oncogenesis and explores studies of VEGF-targeted agents and potential biomarkers in multiple tumor types.
-
In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.
|
Latest Content
-
In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.
Date Posted: 4/14/2017
-
Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
Faculty: Richard Finn MD, Gary K. Schwartz MD, Geoffrey Shapiro MD, PhD
Released: 4/14/2017
-
In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at the 2016 ESMO annual meeting across multiple different malignancies including advanced NSCLC, melanoma, breast cancer, ovarian cancer, and glioblastoma.
Faculty: Margaret Callahan MD, PhD, Shirish Gadgeel MD, Ryan T. Merrell MD, Bradley J. Monk MD, FACS, FACOG, Joyce O'Shaughnessy MD
Released: 1/4/2017
-
In this downloadable slideset, Margaret Callahan, MD, PhD; Shirish Gadgeel, MD; Ryan T. Merrell, MD; Bradley J. Monk, MD, FACS, FACOG; and Joyce O’Shaughnessy, MD, review important clinical presentations across multiple cancers from the 2016 oncology meeting in Copenhagen.
Date Posted: 12/12/2016
-
In these highlights from the ClinicalThought™ program, CCO’s expert faculty members describe how they tackle challenging clinical decisions in the settings of breast cancer, chronic myeloid leukemia, glioblastoma, immune thrombocytopenia, diffuse large B-cell lymphoma, melanoma, multiple myeloma, and prostate cancer.
Faculty: William J. Gradishar MD, FACP, Mohammad Jahanzeb MD, FACP, Elias Jabbour MD, Annick Desjardins MD, FRCPC, David I. Quinn MBBS, PhD, FRACP, FACP, Howard Liebman MD, FACP, Christopher R. Flowers MD, Keith T. Flaherty MD, William I. Bensinger MD, H. Jack West MD
Released: 5/24/2013
-
| Annick Desjardins MD, FRCPC - 1/9/2013 |
8 comments / Last Comment: 7/2/2013 |
New results from a randomized phase III trial show improved PFS and quality of life in newly diagnosed patients with glioblastoma who received bevacizumab and standard therapy. Should we expand our use of bevacizumab into this new setting?
-
Ravi Salgia, MD, provides expert perspective on results of studies of MET-targeted agents being evaluated in a variety of tumor types.
Faculty: Ravi Salgia MD
Released: 7/27/2012
-
Ahmad Tarhini, MD, PhD, reviews the role of the VEGF pathway in oncogenesis and explores studies of VEGF-targeted agents and potential biomarkers in multiple tumor types.
Faculty: Ahmad Tarhini MD, PhD
Released: 6/21/2012
|
|
|